首页> 外文期刊>海南医科大学学报(英文版) >Meta analysis of Masquelet technology and Llizarov technology in the treatment of infectious bone defects
【24h】

Meta analysis of Masquelet technology and Llizarov technology in the treatment of infectious bone defects

机译:Masquelet技术和Llizarov技术在感染性骨缺损治疗中的荟萃分析

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To systematically evaluate the clinical efficacy and safety of Masquelet technology and Llizarov group technology in the treatment of infectious bone defects by meta-analysis. Methods: The computer searched China Knowledge Network (CNKI), Wanfang, VIP, Chinese Biomedical Literature Database (CBM), Pubmed, Medline, Cochrane Llibrary databases. The retrieval time was from the time of the establishment of the database to January 2020. According to the inclusion and exclusion criteria, randomized controlled trials on the treatment of infectious bone defects using Masquelet technology and Llizarov technology were collected, and the retrieved literature was independently screened, evaluated, and data extracted by two researchers, and then RevMan5.3 software was used so for meta-analysis. Results: A total of 10 RCT documents were included, with a total of 496 patients, including 242 in the Masquelet group and 254 in the Llizarov group. The results of the meta-analysis showed that: in terms of bone defect healing time, total weight bearing time, treatment cost, and complication rate, the Masquelet group was significantly different from the Llizarov group, and the Masquelet group was better than the Llizarov group (P <0.05);In terms of knee joint Lowa score and SF-36 score, Masquelet group has significant differences compared with Llizarov group, Llizarov group is better than Masquelet group (P <0.05);in excellent rate, number of operations, ankle Lowa score, infection control rate In terms of excellent rate of affected limb function, there was no significant difference between Masquelet group and Llizarov group (P> 0.05). Conclusion:Compared with Llizarov technology, Masquelet technology has obvious advantages in the treatment of infectious bone defects in terms of bone defect healing time, total weight-bearing time, treatment cost, and complication rate. In terms of scoring, it has advantages over Masquelet technology, but in terms of excellent treatment rate, number of operations, and ankle lowa score. In terms of infection control rate and excellent function of affected limbs, there was no significant difference between Masquelet technology and Llizarov technology,However, due to the low quality of the included studies and the small sample size, the exact efficacy still needs to be confirmed by higher quality RCT studies.
机译:目的:系统地评价MASQUET技术和Llizarov组技术在荟萃分析治疗传染性骨缺陷中的临床疗效和安全性。方法:计算机搜索中国知识网络(CNKI),万芳,VIP,中国生物医学文献数据库(CBM),PubMed,Medline,Cochrane Llibrary数据库。从建立数据库到2020年1月的检索时间。根据纳入和排除标准,收集了使用MASQuelet技术和Llizarov技术治疗传染性骨缺陷的随机对照试验,并且检索的文献独立由两个研究人员提取的筛选,评估和数据,然后使用Revman5.3软件进行Meta分析。结果:总共包括10个RCT文件,共有496名患者,包括梅凯科夫组中的242名,其中Llizarov组中254名。荟萃分析的结果表明:就骨缺损愈合时间而言,总重量轴承时间,治疗成本和并发症率,梅特曲线组与Llizarov组显着不同,并且梅特赛组优于Llizarov组(P <0.05);在膝关节较低的比分和SF-36评分方面,与Llizarov组相比,Masquelet组与Llizarov组相比具有显着的差异(P <0.05);以优异的速度,操作数量,踝关节低层评分,感染控制率在患有肢体率优异的率方面,梅凯特组和Llizarov组之间没有显着差异(P> 0.05)。结论:与Llizarov技术相比,MASQUELET技术在骨缺损愈合时间,总重量时间,治疗成本和并发症率方面治疗传染性骨缺损的明显优势。在评分方面,它具有优势,具有梅芳技术,但就优异的处理率,运营数量和脚踝Lowa得分而言。在感染控制率和受影响的四肢的优异功能方面,梅泰特技术和Llizarov技术之间没有显着差异,然而,由于所包含的研究和小样本量小,因此需要确认确切的功效通过更高质量的RCT研究。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号